

Literatúra

1. MARX, R. E.: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg* 2003, 61 (9), p. 1 115–1 117.
2. LASSETER, K. C., PORRAS, A. G., DENKER, A., et al.: Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. *Clin Drug Investig.*, 2005, 25 (2), p. 107–114.
3. OWOSHO, A. A., BLANCHARD, A., LEVI, L., et al.: Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients. *J Cran Maxillo Fac Surg* 2016, 40 (2), p. 265–270.
4. JUNG, T-Y.: Osteonecrosis of jaw after antiangiogenic agent administration in a renal cell carcinoma patient. *Oral maxillofac Surg Cases*, 2017, 3, p. 27–33.
5. OTTO, S., PAUTKE, CH., et al.: Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. *Cancer treatment reviews*, 2018, 69 (2), p. 177–187.
6. OTTO, S., RISTOW, O., et al.: Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: A prospective cohort study. *J Cranio Maxillofac Surg*, 2016, 44, p. 1 073–1 080.